Understanding Carvykti®

Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) after at least 1 prior line of therapy. Carvykti is the first BCMA-targeted therapy approved for myeloma as early as at first relapse. Carvykti uses a patient’s own T cells, which are collected and genetically engineered, then reinfused into the patient to seek out and kill the patient’s myeloma cells.